When was Meissa Vaccines founded?

Meissa Vaccines was founded in 2014 and raised its 1st funding round 3 years after it was founded.

Where is Meissa Vaccines located?

Meissa Vaccines is headquartered in Redwood City, United States. It is registered at Rīga, Sporta iela 7 - 7.

How many employees does Meissa Vaccines have?

As of Jul 01, 2024, the latest employee count at Meissa Vaccines is 26.

Is Meissa Vaccines a funded company?

Meissa Vaccines is a funded company, having raised a total of $33.4M across 9 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 01, 2017.

When was the latest funding round of Meissa Vaccines?

Meissa Vaccines' latest funding was a $***** Series A round on Sep 26, 2019, with participation from 1 investor.

Where does Meissa Vaccines rank among its competitors?

Meissa Vaccines ranks 89th amongst 356 active competitors, of which 96 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was eradivir, which secured $10M in Oct, 2025.

Who are the top competitors of Meissa Vaccines?

Meissa Vaccines' top competitors include Bharat Biotech, Immunocore and HOOKIPA Pharma. Among them, eradivir secured the most recent funding round in October, 2025.

Meissa Vaccines - 2026 Company Profile, Funding & Competitors

Meissa Vaccines is a series A company based in Redwood City (United States), founded in 2014. It operates as a Film and TV production company specializing in documentaries and investigative journalism. Meissa Vaccines has raised $33.4M in funding from Morningside and MBX Capital. The company has 356 active competitors, including 96 funded and 89 that have exited. Its top competitors include companies like Bharat Biotech, Immunocore and HOOKIPA Pharma.

Company Details

Film and TV production company specializing in documentaries and investigative journalism. The company creates and directs films and television programs, focusing on travel, culture, and social issues. Their work includes documentaries, investigative reports, and short films. They explore diverse topics, from the origins of horse breeds to the impact of illegal activities. The company offers content creation, direction, and production services for various media platforms. They are involved in storytelling, filmmaking, and investigative reporting. Their work aims to inform and engage audiences with compelling narratives and in-depth explorations of global issues.

Website: meissavaccines.com
Social
Email ID: *****@meissavaccines.com
Registered Address: Rīga, Sporta iela 7 - 7

Key Metrics

Founded Year

2014

Location

Redwood City, United States

Stage

Series A

Total Funding

$33.4M in 9 rounds

Latest Funding Round

Series A, Sep 26, 2019, $*****

Investors

Morningside & 5 more

Ranked

89^th among 356 active competitors

Employee Count

26 as on Jul 01, 2024

Similar Companies

Bharat Biotech & 436 more

View Meissa Vaccines' full profile

Meissa Vaccines is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Meissa CIN: 40003598112 , Latvia, Active	Jul 26, 2002	$0 - $1M (As on Dec 31, 2024)	6 (As on Dec 31, 2023)	-

Meissa Vaccines has raised a total funding of $33.4M over 9 rounds. Its first funding round was on Apr 01, 2017. Its latest funding round was a Series A round on Sep 26, 2019 for $*****. 1 investor participated in its latest round. Meissa Vaccines has 6 institutional investors.

Here is the list of recent funding rounds of Meissa Vaccines:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 26, 2019	6630739	Series A	1453070	9045636	4475177	2809782
Jun 26, 2019	5345043	Grant (prize money)	9710687	1850162	6485584	HHS
Mar 27, 2019	4160732	Seed	2717406	1186345	1355770	5883054

Access funding benchmarks and valuations. Sign up today!

View details of Meissa Vaccines's funding rounds and investors

Meissa Vaccines' employee count trend

Meissa Vaccines has 26 employees as of Jul 24. Here is Meissa Vaccines's employee count trend over the years:

Employee count trend for Meissa Vaccines

Uncover Meissa Vaccines' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Meissa Vaccines include Bharat Biotech, Immunocore and HOOKIPA Pharma. Here is the list of Top 10 competitors of Meissa Vaccines, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Bharat Biotech 1996, Hyderabad (India), Early Stage	Manufacturer of vaccines and bio-therapeutic products	$13.7M	ICICI Venture, IFC & 25 others	69/100
2nd	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	BlackRock, Woodford Investment Management ... & 50 others	69/100
3rd	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	Sofinnova Partners, Forbion & 12 others	68/100
4th	Vaxart 2004, San Francisco (United States), Public	Developer of therapeutic solutions for treating multiple infectious diseases	$58M	Quantum Technology Partners, Life Science Angels ... & 8 others	67/100
5th	Valneva 1999, Lyon (France), Public	Developer of prophylactic vaccines for infectious diseases	$114M	MPM Capital, Eiffel Investment Group & 13 others	67/100
6th	Atea 2014, Boston (United States), Public	Developer of therapeutics for viral diseases	$293M	GSA Capital Partners, Bain Capital & 18 others	67/100
7th	Leyden Labs 2020, Amsterdam (Netherlands), Series B	Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa	$257M	Google Ventures, Casdin Capital & 11 others	64/100
8th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	HongShan, Invesco & 7 others	63/100
9th	Stallergenes Greer 2013, London (United Kingdom), Acquired	Developing allergen immunotherapy (vaccine) for respiratory allergies	-	Waypoint Capital, B-FLEXION	62/100
10th	eradivir 2020, West Lafayette (United States), Series A	Developer of immunotherapies for the treatment of infectious diseases	$20.3M	Research Bridge Partners, America’s Seed Fund ... & 2 others	62/100
89th	Meissa Vaccines 2014, Redwood City (United States), Series A	Film and TV production company specializing in documentaries and investigative journalism	$33.4M	Morningside, MBX Capital & 4 others	44/100